Last update 24 Dec 2024

Ketamine Hydrochloride

Last update 24 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryKetamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting.

Drug Type

Small molecule drug

Synonyms

(+-)-Ketamine, (±)-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [36]

Target

NMDA receptor

Mechanism

NMDA receptor modulators(Glutamate [NMDA] receptor modulators)

Therapeutic Areas

Other DiseasesNervous System DiseasesCongenital Disorders+ [5]

Active Indication

AnesthesiaPainBipolar and Related Disorders+ [18]

Inactive Indication

Amyotrophic Lateral SclerosisAutism Spectrum DisorderBunion+ [5]

Originator Organization

Endo International Plc

Active Organization

PharmaTher Holdings Ltd.

NeuroRx, Inc.

Seelos Therapeutics, Inc.

+ [17]

Inactive Organization

Novartis Pharma AG

Douglas Pharmaceuticals Ltd.Cch Pharma Pty Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (19 Feb 1970),

Anesthesia

RegulationFast Track (US), Innovative Licensing and Access Pathway (GB), Orphan Drug (US)

Structure

Molecular FormulaC13H17Cl2NO

InChIKeyVCMGMSHEPQENPE-UHFFFAOYSA-N

CAS Registry1867-66-9

1,870

Clinical Trials associated with Ketamine Hydrochloride

IRCT20161022030421N3 / SuspendedPhase 3IIT

Comparison of the effect of intravenous ketamine and midazolam as a premedication in children undergoing cochlear implantation at the time of separation from parents

Start Date21 Jan 2640

Sponsor / Collaborator-

NCT05945147 / WithdrawnPhase 2IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

Start Date01 Jan 2099

Sponsor / Collaborator

Stanford University

NCT04291521 / Not yet recruitingNot ApplicableIIT

Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes

To compare the outcomes of the use of propofol, etomidate, and ketamine as induction agents for adult trauma patients undergoing intubation within 24 hours of admission. The primary goal is to determine the ideal agent that should be used in this patient population for intubations.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Southern California

[+4]

100 Clinical Results associated with Ketamine Hydrochloride

100 Translational Medicine associated with Ketamine Hydrochloride

100 Patents (Medical) associated with Ketamine Hydrochloride

27,301

Literatures (Medical) associated with Ketamine Hydrochloride

01 Mar 2025·JOURNAL OF AFFECTIVE DISORDERS

Clinical indicators of the suicide crisis and response to ketamine

Article

Author: Neely, Lucinda ; Zarate, Carlos A ; Waldman, Laura ; Ballard, Elizabeth D ; Greenstein, Dede

BACKGROUND:

This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation at the time of suicide crisis and responsiveness to rapid-acting interventions. Suicidal ideation (SI), depression, and hopelessness were hypothesized to meet these criteria.

METHODS:

Participants were 118 adults across the continuum of suicide risk, including 14 high-risk (HR) individuals who had attempted or seriously considered suicide within the last two weeks. Clinical characteristics were evaluated by: 1) comparing individuals with a recent crisis state to those whose suicide crises had resolved; 2) quantifying responses to a semi-structured interview about the time just before a suicide crisis; and 3) comparing symptomatology before and after an open-label ketamine infusion (0.5 mg/kg) in a subset of the HR group (n = 10).

RESULTS:

As hypothesized, SI, depression, and hopelessness were elevated just after a suicide crisis and responded to ketamine, although findings were mixed depending on the assessment used. Psychological pain and traumatic stress symptoms were also associated with the suicide crisis and responded to ketamine. Participants reported high levels of SI, depression, and anxiety just before their suicide attempt.

LIMITATIONS:

Limitations include the small sample size, inconsistent assessments across analyses, and that ketamine was the only intervention examined.

CONCLUSIONS:

These results underscore the importance of SI, depression, hopelessness, psychological pain, and traumatic stress in this population, all of which were elevated during the suicide crisis and responded to ketamine. A multifactorial and longitudinal approach is indicated to assess and treat suicide risk.

01 Feb 2025·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

5-HT1B receptor activation produces rapid antidepressant-like effects in rodents

Article

Author: Hu, Tingting ; Li, Fugang ; Gallero-Salas, Yasir ; Bristow, Linda J ; Hanania, Taleen ; Kretschmannova, Karla ; Koblan, Kenneth S ; Clark, Erin A ; Dedic, Nina ; Jagger, Elizabeth ; Bianchi, Massimiliano ; Wang, Lien

Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most research has focused on glutamatergic mechanisms, recent studies show that antidepressant-like effects in rodents are dependent upon the serotonergic (5-HT) system and suggest a potential contribution of the 5-HT_1B receptor. In this study we utilized CP-94253 to examine whether 5-HT_1B receptor agonism produces rapid and sustained antidepressant-like effects, focusing on rodent models and treatment approaches commonly used to demonstrate the differentiated response to ketamine. We first confirmed that CP-94253 is a potent 5-HT_1B agonist in vitro and that CP-94253 occupies brain 5-HT_1B receptors at the doses tested. CP-94253 reduced immobility in the mouse forced swim test (FST) and exhibited a prominent antidepressant signature in the mouse-behavior phenotyping platform SmartCube®. When examined 24 h after acute treatment, CP-94253 reduced FST immobility in both naïve rats and in rats receiving chronic interferon alpha treatment. Ex vivo hippocampal long-term potentiation was also enhanced in naïve rats receiving acute CP-94253 treatment, 24 h prior to the recordings. In mice exposed to chronic social defeat stress, antidepressant-like effects in the tail suspension and sucrose preference tests were seen 1 h and 24 h after acute treatment, respectively. Finally, whole brain c-fos imaging in mice showed that CP-94253 modulates neuronal activity in discrete brain regions including the lateral habenula circuit implicated in depression and the ketamine treatment response. Collectively these results support the further investigation of 5-HT_1B agonism as a novel treatment approach for major depressive disorder.

01 Feb 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Agitation: Neurobiology and current management guidelines

Review

Author: Van Remmen, Sarah ; Mahmood, Sara ; Rullo, Mario ; Miller, Christopher W T

There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency services. This manuscript provides a synthesis of current recommendations, combined with a detailed breakdown of the neurobiology of agitation, linking these neuroscientific dimensions with the pharmacological profiles of the drugs recommended by practice guidelines (as well as the profiles of other important agents). Since Project BETA (Best Practices in Evaluation and Treatment of Agitation) guidelines were published in 2012 (by the American Association for Emergency Psychiatry), there have been several developments in the standard of care, including an increase in use of ketamine and droperidol. Recommended treatment strategies for clinicians will be presented, including consideration of how to address specific causes of agitation.

594

News (Medical) associated with Ketamine Hydrochloride

19 Dec 2024

·www.accesswire.com

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Erez Aminov, Chairman & CEO of Mira, stated: "This IND submission highlights our team's commitment to executing efficiently as we advance transformative therapies. Ketamir-2 not only has demonstrated remarkable potential for neuropathic pain but also offers a broad opportunity across other major neuropsychiatric conditions. We look forward to beginning Phase I trials and continuing to deliver on our mission to address unmet medical needs."The IND application includes comprehensive data and reports detailing Ketamir-2's pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models. In parallel with the submission, the company is preparing to conduct a complementary neurotoxicity study, as required by the FDA's written feedback to the pre-IND documentation.According to a market analysis report from Fortune Business Insights, the neuropathic pain market in North America, including the United States, Canada, and Mexico, is valued at $3.1 billion and is expected to grow at a 6-7% compound annual growth rate (CAGR), reaching $4.5 billion by 2030. Despite this growth, existing treatments remain inadequate. Gabapentin and pregabalin, while widely prescribed, provide limited efficacy and are associated with side effects such as sedation, dizziness, and weight gain. Opioids remain a common treatment option but come with well-known risks of dependency, addiction, and respiratory depression. Intravenous ketamine, though effective for some patients, requires invasive administration and is often associated with psychotropic side effects, including hallucinations and dissociation.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein (P-gp), which allows for better oral absorption and enhanced blood-brain barrier penetration. Unlike traditional ketamine, Ketamir-2 does not cause sedation or hyperactivity-side effects often linked to psychiatric conditions such as schizophrenia, bipolar mania, and ADHD. As a non-opioid therapy, Ketamir-2 is designed to eliminate the risks of dependency and addiction. Additionally, the DEA has determined that Ketamir-2 is not a controlled substance, streamlining accessibility and minimizing regulatory hurdles.Preclinical studies have demonstrated Ketamir-2's ability to achieve 100% pain reversal, fully normalizing pain thresholds in validated neuropathic pain models. Furthermore, Ketamir-2 has shown a strong safety and toxicological profile, observed across cardiovascular, CNS, respiratory, or toxicology assessments.Dr. Itzchak Angel, Chief Scientific Advisor at Mira, commented: "Ketamir-2's selective mechanism of action, strong safety profile, and ability to achieve full pain reversal underscore its potential as a transformative therapy."With the IND submitted, MIRA expects to initiate Phase I Clinical Trials in Q1 2025 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Phase IIa trials are expected to follow in late 2025 to assess efficacy in neuropathic pain patients. Beyond neuropathic pain, the company is exploring additional indications for Ketamir-2, including MDD, MDD-SI, TRD and PTSD.About MIRA Pharmaceuticals, Inc.MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.Contact InformationHelga Moya [email protected](786) 432-9792SOURCE: Mira Pharmaceuticals, Inc.

Phase 1Phase 2IND

18 Dec 2024

·www.globenewswire.com

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study is designed to assess the pharmacokinetics of Silo’s dissolvable ketamine-based injectable implant, SP-26, in a minipig model. SP-26 is being developed as a self-administered, non-opioid therapeutic aimed at treating chronic pain and fibromyalgia. The non-GLP study, set to span three weeks, will investigate the absorption, distribution, metabolism, and excretion (ADME) of extended-release ketamine hydrochloride implants. Two distinct polymer formulations will be tested at varying dose levels. “So far this year we have conducted several studies of our SP-26 ketamine implants including analytical testing and small batch proof-of-concept extrusion trials, manufacturing and production evaluation, and sterilization and dissolution tests, with what we believe are encouraging results,” said Silo CEO Eric Weisblum. “The advancement of this program into animal studies is an important milestone achievement as we work to bring a safe and effective and to our knowledge, first-of-its-kind ketamine treatment for those living with chronic pain.” “AmplifyBio is honored to support Silo Pharma in this critical safety milestone for SP-26. We understand and take seriously the trust put in us to execute the PK study efficiently and with excellence,” said Jerry Hacker, EVP, and Chief Commercial Officer for AmplifyBio. About SP-26 SP-26 is a ketamine-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant is being designed to safely regulate dosage and time release of the pain-relieving treatment. If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information, visit www.silopharma.com and connect on social media at LinkedIn , X , and Facebook . Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this news release, whether as a result of new information, future events, or otherwise, after the date of this news release or to reflect the occurrence of unanticipated events except as required by law. Contact 800-705-0120 investors@silopharma.com

Clinical Study

12 Dec 2024

·www.businesswire.com

Gate Neurosciences Presents New Data and Insights Highlighting Unique Pharmacology of Synaptic Function Modulators at the 2024 ACNP Annual Meeting

INDIANAPOLIS--( BUSINESS WIRE )-- Gate Neurosciences , a synaptic health biotechnology company focused on advancing next-generation precision central nervous system (CNS) treatments, today announced new research presented at the recently concluded 2024 annual meeting of the American College of Neuropsychopharmacology (ACNP), held in Phoenix from December 8-11, 2024. “The synapse is a therapeutic target, and we are determined to communicate our novel findings on the unique pharmacology of modulating synapses. Our new research presented at ACNP this week can help to uncover the massive potential of molecules that address synaptic weakening underlying many CNS diseases,” stated Mike McCully, president and CEO of Gate Neurosciences. “Synaptic function-enhancing molecules like ketamine and our ‘stinel programs operate in a fundamentally different paradigm than traditional CNS drugs that require constant time on-target to work. Our new translational insights clearly highlight that dosing frequency influences the short and long-term effectiveness of these types of molecules and is a critical factor to their successful development.” The two ACNP presentations detailed new insights on the pharmacology of molecules that enhance synaptic function and neuroplasticity, including both ketamine and Gate’s lead program, zelquistinel (GATE-251), and highlighted Gate’s emerging translational work to optimize dosing dynamics. A hallmark of both ketamine and zelquistinel is that a single dose triggers rapid, long-lasting metaplasticity effects on synapses which persist well-beyond clearance from their target receptors — a phenomenon termed “event-driven pharmacology.” New preclinical data shared by Gate at the ACNP conference demonstrate that optimizing dose level and dose frequency using translational measures of synaptic strength and plasticity may be necessary to maximize therapeutic effects and avoid loss of efficacy. Zelquistinel is currently in Phase 2 development (VITALIZE Study) as a once-weekly oral treatment for depression and other diseases of synaptic dysfunction such as Alzheimer’s cognition and schizophrenia. ACNP Poster Presentation Details Title: Zelquistinel, a Novel NMDAR Modulator with Rapid-Acting & Sustained Effects: Optimizing Dose and Dose Interval Based on Translational Measures of Synaptic Plasticity Abstract Number: P208 Lead Author: Jeffrey Burgdorf, Ph.D. Summary: In vivo effects on NMDA receptor-mediated synaptic modulation, duration of plasticity and metaplasticity, and emotional learning were assessed following single, daily, and once-weekly dosing of zelquistinel in mice. Single doses of zelquistinel enhanced synaptic strength and learning, daily dosing actively suppressed this beneficial effect, and weekly dosing sustained or increased the beneficial effects. Title: More May Not Be Better: Ketamine Dosing Frequency Modulates Synaptic Strength, Metaplasticity and Emotional Learning Abstract Number: P215 Lead Author: John Donello, Ph.D. Summary: Single doses versus five daily doses of ketamine were compared in mice. Single doses of ketamine had electrophysiological and behavioral effects lasting for seven days, including enhanced in vivo synaptic strength, positively impacted metaplasticity, and enhanced emotional learning behavior. Five daily repeated doses of ketamine actively suppressed the beneficial effects of the drug. Full abstracts are published by ACNP and are available on the organization’s website . Other recent insights on the unique pharmacology of synaptic function-enhancing molecules shared by Gate Neurosciences and others include: the white paper, “Reshaping Neuropsychiatry,” 1 by Dr. Anantha Shekhar, co-founder of Gate Neurosciences; presentations at this year’s ASCP annual meeting 2 on emerging dosing concepts; and recent publications on zelquistinel’s mechanism of action, 3 preclinical data on ketamine metaplasticity, 4 and clinical data showing the loss of efficacy with daily ketamine dosing. 5 Shekhar, A. (2024, August 7). Reshaping neuropsychiatry. Drug Discovery World (DDW) . https://www.ddw-online.com/reshaping-neuropsychiatry-31040-202408/ Gate Neurosciences to share new data and research on its synaptic function molecules with multiple posters at 2024 ASCP meeting. (2024, May 15). Gate Neurosciences https://www.gateneuro.com/press-releases/gate-neurosciences-to-share-new-data-and-research-on-its-synaptic-function-molecules-with-multiple-posters-at-2024-ascp-meeting Zhang, X., Li, Y.-X., Berglund, N., Burgdorf, J. S., Donello, J. E., Moskal, J. R., & Stanton, P. K. (2024). Zelquistinel acts at an extracellular binding domain to modulate intracellular calcium inactivation of N-methyl-D-aspartate receptors Neuropharmacology , 259 , 110100. https://doi.org/10.1016/j.neuropharm.2024.110100 Brown, K. A., & Gould, T. D. (2024). Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Molecular Psychiatry , 29 (4), 1114–1127. https://doi.org/10.1038/s41380-023-02397-1 Pattanaseri, K., Lortrakul, J., Jaisin, K., Srifuengfung, M., Sa-nguanpanich, N., Viravan, N., Pariwatcharakul, P., Makarasara, W., & Ratta-apha, W. (2024). A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression. BMC Psychiatry , 24 (1). https://doi.org/10.1186/s12888-024-05951-5 About Gate Neurosciences Gate Neurosciences is a synaptic health biotechnology company focused on advancing next-generation precision CNS treatments that address growing needs in mental health. The company is developing a portfolio of novel mechanisms of action that enhance synaptic function to address neuropsychiatric and neurocognitive diseases, including major depressive disorder (MDD). Using learnings from extensive clinical, preclinical, and translational data and a better understanding of CNS development challenges, the company is advancing its clinical pipeline using evidence-driven, precision psychiatry approaches.

Phase 2

100 Deals associated with Ketamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00711	Ketamine Hydrochloride	N01AX03	DBSALT000396

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Endo Operations Ltd.	19 Feb 1970
Pain	CA	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar and Related Disorders	Phase 3	US	NeuroRx, Inc.	30 Jan 2022
Depressive Disorder	Phase 3	US	NeuroRx, Inc.	25 Jun 2019
Suicidal Ideation	Phase 3	US	NeuroRx, Inc.	25 Jun 2019
Alcohol Use Disorder	Phase 3	GB	Awakn Life Sciences Corp.	-
Stress Disorders, Post-Traumatic	Phase 2	US	Seelos Therapeutics, Inc.	27 Nov 2023
Rett Syndrome	Phase 2	US	PharmaTher Holdings Ltd.	02 Feb 2023
Dyskinesia, Drug-Induced	Phase 2	US	Pharmather, Inc.	05 Oct 2021
Parkinson Disease	Phase 2	US	Pharmather, Inc.	05 Oct 2021
Cluster Headache	Phase 2	DK	Cch Pharma Pty Ltd.	20 Nov 2019
Depressive Disorder, Major	Phase 2	AU	Douglas Pharmaceuticals Ltd.	30 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Anemia, Sickle Cell	-	Ketamine use	cfmrcurylx(wudqqblgyw) = pxfplgcoht rbwejazfhr (zwnyvozcgl, 4 - 10) View more	-	08 Dec 2024
				No ketamine use	cfmrcurylx(wudqqblgyw) = yonfkohppe rbwejazfhr (zwnyvozcgl, 1 - 4) View more
NCT04260607 (CTgov)	Phase 3	Depressive Disorder \| Suicidal Ideation	1	Ketamine Hydrochloride (Experimental-Ketamine)	jefmxziald(rqeqeevqcq) = mkdupsvvey rdilxukkrj (fuhvfdplph, wdnupebkip - nxrkynlkim) View more	-	19 Nov 2024
				normal saline (Placebo-Saline)	axyvxikwku(dkwffleeyq) = dmdpazwtwj gavebusbhr (fhpyxhmpda, ehppaofbhj - nnsntlhwfe) View more
NCT04022226 (CTgov)	Early Phase 1	Depressive Disorder	11	Methohexital	carddiahnk(gkiouekvdy) = vtgdbjzjkz zpvczhznyd (njjggsrdvz, lgbycghdbz - xhhohfugix) View more	-	26 Oct 2024
NCT04889664 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	16	Written Exposure Therapy+ketamine	syfxdsqvru(obtajvqrmd) = jnroczkmja mbaiyznmur (nozubqqedx, knscabmyum - tqajywudzk) View more	-	08 Oct 2024
SFN2024	Not Applicable	Schizophrenia	-	Ketamine	ingzjmzzyk(qxhtotztbf) = cqgukyfehx neajoblxfb (doyzofoerm ) View more	-	05 Oct 2024
				Saline	ingzjmzzyk(qxhtotztbf) = firmqmgkaq neajoblxfb (doyzofoerm )
NCT04916548 (CTgov)	Phase 1/2	Depressive Disorder	15	Intravenous Ketamine	urhsjcvtim(ietrzevdsp) = tptsmdfgod jlddzphmgm (trgihcshfm, ityvkukpnp - hndycxmluj) View more	-	20 Aug 2024
NCT05168735 (CTgov)	Phase 1/2	Depressive Disorder	43	Brief Mindfulness Exercises+Intravenous Ketamine (Intravenous Ketamine + Mindfulness Exercises)	touvmacfij(ktrhdkzhla) = tygnlmoclr gjfdcqxsxy (szxyweelgr, sigwrwfpec - noodvvkkeo) View more	-	20 Aug 2024
				Academic Exercises+Intravenous Ketamine (Intravenous Ketamine + Academic Exercises)	touvmacfij(ktrhdkzhla) = ytuevzlffb gjfdcqxsxy (szxyweelgr, zqspxvppcy - wjveqirpfh) View more
NCT05957302 (Pubmed \| J Anesth) Manual	Not Applicable	Shock, Septic	86	Ketamine 1 mg/kg	ydabfjjlzt(ijqpdlgzry) = gmzhjqclna fojkursdcs (vbzcbysrqj )	Positive	18 Aug 2024
				fentanyl 1 mg/kg	ydabfjjlzt(ijqpdlgzry) = fwgfgstjke fojkursdcs (vbzcbysrqj )
NCT04947085 (CTgov)	Phase 4	Pain	150	Ketamine via Intravenous (IV SDK)	oinxgidihn(pebjdabxfk) = ksezmtmeen lbkvvqvbgs (ielebybcqm, osktyyrvqn - xrbimiwqpo) View more	-	03 Jul 2024
				Ketamine via BAN (K-BAN)	oinxgidihn(pebjdabxfk) = lmcchhltti lbkvvqvbgs (ielebybcqm, omlmektnyj - txfysvpgfm) View more
NCT06236113 (CTgov)	Phase 4	Rib Fractures	50	Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Placebo/Control)	ghfyivlwil(skvizfmrwb) = gqpmasrjxq jpryeuebuo (bohvbghqfb, uzvvfwdrgb - crysqvsjki) View more	-	21 May 2024
				Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Low Dose Ketamine Infusion (LDKI))	ghfyivlwil(skvizfmrwb) = usvhnksfwl jpryeuebuo (bohvbghqfb, epgjmphnui - lfguuhxejm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis